COST-FIN Study shared a post on LinkedIn:
“Proud to see our COST-FIN PI, Dr. Juliet Siena Lumati, presenting at ARGO on ‘Optimum Approach to the Management of Localized Pancreas Cancer: Upfront Resection vs Neoadjuvant Chemotherapy.’
Sharing her expertise in surgical oncology, Dr. Lumati brings attention to critical decisions in pancreatic cancer treatment.
We’re proud of her leadership in advancing cancer care and addressing the financial barriers patients face in accessing it.”
You can also read: PACT-21 CASSANDRA: Preoperative Chemotherapy Duration in Resectable and Borderline Resectable PDAC
